Muttenz-based startup accroma labtec Ltd., specialising in lab automation systems, has acquired LabMinds’ product range and IP. As the leading supplier for automated preparation of solutions serving more than 50% of the top 30 pharmaceutical companies, the asset deal gives accroma access to a broader customer base and the North American market.
A specialist in automated sample preparation of solid and semi-solid samples, accroma labtech develops, manufactures, and distributes its laboratory automation systems worldwide, which automates the entire sample preparation process from sample to injection. Applications include quality control of oral solid dosages and pesticide residue determination in food. The solution solves a major efficiency and reliability problem of laboratories. The company offers a sample preparation system,
Buffer solutions are widely used in the biopharmaceutical industry. However, as Stefan Gafner, CEO of accroma, explains, “the preparation of buffer solutions in laboratories is very labour-intensive and a real bottleneck, like sample preparation of solid and semi-solid samples. In addition to being time-consuming, accuracy, repeatability, and traceability are real challenges with these manual processes. Therefore, there is a huge potential for automation in laboratories.”
To expand its offering, the Swiss startup has acquired the assets of Boston and UK-Based company LabMinds. This acquisition allows customers to benefit from in-depth automation knowledge and services that stand out from the well-known pipetting automation solutions and cover the largest bottlenecks, sample and solution preparation. In addition, thanks to the cloud solution already established and accepted by pharmaceutical customers, they can remotely access different robots for different areas in the laboratory via a single interface.
“Together with our sample preparation system, the Revo platform from LabMinds offers the optimal addition to the product portfolio and addresses the second main bottleneck in labs today. Through the acquisition, our customers will benefit massively from the consolidated technology platform and standardised services in these demanding and regulated environments.”
More than 50% of the top 30 pharmaceutical companies use LabMinds technology, among others, at several sites, which impressively shows the need for the technology. accroma intends to invest in the further development of the technology to eventually enable a fully digital, cloud-connected and AI-powered Lab 4.0. This will allow the pharmaceutical industry to develop faster, more reliable, less expensive and highly effective therapies.
Following the acquisition, accroma will retain its headquarters in Muttenz, Northwestern Switzerland, while the LabMinds office in Boston will serve as a service, support and logistics center for the North American market. In order to ensure the highest possible stability, key LabMinds employees in both Boston and Oxford will be taken over by accroma.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines